Literature DB >> 26327445

Relevance of 3D magnetic resonance imaging sequences in diagnosing basal subarachnoid neurocysticercosis.

Roger Carrillo Mezo1, Javier Lara García1, Mariana Arroyo2, Agnès Fleury3.   

Abstract

Imagenological diagnosis of subarachnoid neurocysticercosis is usually difficult when classical magnetic resonance imaging (MRI) sequences are used. The purpose of this study was to evaluate the advantages of 3D MRI sequences (Fast Imaging Employing Steady-state Acquisition (FIESTA) and Spoiled Gradient Recalled Echo (SPGR)) with respect to classical sequences (Fluid Attenuation Inversion Recovery (FLAIR) and T1) in visualizing Taenia solium cyst in these locations. Forty-seven T. solium cysts located in the basal cisterns of the subarachnoid space were diagnosed in eighteen Mexican patients. A pre-treatment MRI was performed on all patients, and all four sequences (FIESTA, FLAIR, T1 SPGR, and T2) were evaluated independently by two neuroradiologists. The sensitivity of each sequence to detect the parasite membrane and scolex was evaluated, along with its capacity to detect differences in signal intensity between cerebrospinal fluid (CSF) and cysts. FIESTA sequences allowed the visualization of cyst membrane in 87.2% of the parasites evaluated, FLAIR in 38.3%, SPGR in 23.4%, and T2 in 17.0%. The superiority of FIESTA sequences over the other three imaging methods was statistically significant (P<0.001). Scolices were detected by FIESTA twice as much as the other sequences did, although this difference was not significant (P>0.05). Differences in signal intensity between CSF and parasite cysts were significant in FIESTA (P<0.0001), SPGR (P<0.0001), and FLAIR (P=0.005) sequences. For the first time, the usefulness of 3D MRI sequences to diagnose T. solium cysts located in the basal cisterns of the subarachnoid space was demonstrated. The routine use of these sequences could favor an earlier diagnosis and greatly improve the prognosis of patients affected by this severe form of the disease.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Basal subarachnoid cyst; Diagnosis; MRI 3D sequences; Mexico; Neurocysticercosis

Mesh:

Year:  2015        PMID: 26327445     DOI: 10.1016/j.actatropica.2015.08.017

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  14 in total

1.  A Novel, Highly Sensitive Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and Ventricular Neurocysticercosis and for Assessing Responses to Treatment.

Authors:  Elise M O'Connell; Sarah Harrison; Eric Dahlstrom; Theodore Nash; Thomas B Nutman
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

Review 2.  Update on the Diagnosis and Management of Neurocysticercosis.

Authors:  Camille M Webb; A Clinton White
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

3.  Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  A Clinton White; Christina M Coyle; Vedantam Rajshekhar; Gagandeep Singh; W Allen Hauser; Aaron Mohanty; Hector H Garcia; Theodore E Nash
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

4.  Clinical Symptoms, Imaging Features and Cyst Distribution in the Cerebrospinal Fluid Compartments in Patients with Extraparenchymal Neurocysticercosis.

Authors:  Rodrigo Bazan; Pedro Tadao Hamamoto Filho; Gustavo José Luvizutto; Hélio Rubens de Carvalho Nunes; Newton Satoru Odashima; Antônio Carlos Dos Santos; Jorge Elias Júnior; Marco Antônio Zanini; Agnès Fleury; Osvaldo Massaiti Takayanagui
Journal:  PLoS Negl Trop Dis       Date:  2016-11-09

5.  Treatment of racemose neurocysticercosis.

Authors:  Samuel G McClugage; Rachael A Lee; Bernard C Camins; Juan J Mercado-Acosta; Martin Rodriguez; Kristen O Riley
Journal:  Surg Neurol Int       Date:  2017-08-01

6.  Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features.

Authors:  Mariana Marcin Sierra; Mariana Arroyo; May Cadena Torres; Nancy Ramírez Cruz; Fernando García Hernández; Diana Taboada; Ángeles Galicia Martínez; Tzipe Govezensky; Edda Sciutto; Andrea Toledo; Agnès Fleury
Journal:  PLoS Negl Trop Dis       Date:  2017-06-09

7.  Validity of a PCR assay in CSF for the diagnosis of neurocysticercosis.

Authors:  Arturo Carpio; Alfredo Campoverde; Matthew L Romo; Lorena García; Luis M Piedra; Mónica Pacurucu; Nelson López; Jenner Aguilar; Sebastian López; Luis C Vintimilla; Ana M Toral; Pablo Peña-Tapia
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-01-16

8.  Next-generation sequencing combined with serological tests based pathogen analysis for a neurocysticercosis patient with a 20-year history:a case report.

Authors:  Bin Chen; Zheng Chen; Yi-Shu Yang; Gui-Lan Cai; Xiao-Jiao Xu; Hong-Zhi Guan; Hai-Tao Ren; Hou-Zhen Tuo
Journal:  BMC Neurol       Date:  2021-06-24       Impact factor: 2.474

Review 9.  Pediatric neurocysticercosis: current challenges and future prospects.

Authors:  Pratibha Singhi; Arushi Gahlot Saini
Journal:  Pediatric Health Med Ther       Date:  2016-03-08

10.  Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  A Clinton White; Christina M Coyle; Vedantam Rajshekhar; Gagandeep Singh; W Allen Hauser; Aaron Mohanty; Hector H Garcia; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2018-04       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.